Neuropathy News and Research RSS Feed - Neuropathy News and Research

Diabetic patients at risk for developing retinal diabetic neuropathy

Diabetic patients at risk for developing retinal diabetic neuropathy

A University of Iowa-led study of diabetes-related vision impairment holds good news -- and some bad news -- for patients with signs of these disorders. [More]
RA patients more likely to experience hearing loss

RA patients more likely to experience hearing loss

RA is the commonest autoimmune arthritis affecting 1% of the general population. Despite its main articular manifestations, RA caninvolveextra-articular organs including the auditory system. [More]
Multivitamin use prior to diagnosis may reduce effects of CIPN in breast cancer survivors

Multivitamin use prior to diagnosis may reduce effects of CIPN in breast cancer survivors

Researchers at Roswell Park Cancer Institute, in collaboration with investigators from the cooperative group SWOG, have found that use of multivitamins prior to diagnosis may reduce the risk of neuropathy in breast cancer patients treated with the class of drugs known as taxanes. The team will present their findings at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans. [More]
New drug combination before surgery may improve outcomes in breast cancer patients

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. [More]
Small fibre neuropathy defies 'dying-back' nerve process

Small fibre neuropathy defies 'dying-back' nerve process

Neuronal degradation in patients with small fibre neuropathy is not dependent on nerve fibre length, study findings suggest. [More]
Scientists discover underlying mechanisms of nerve damage

Scientists discover underlying mechanisms of nerve damage

Recent research by Sandra Rieger, Ph.D., of the MDI Biological Laboratory identifying the underlying mechanisms of peripheral neuropathy, or nerve damage, has raised the prospect that drug therapies can be developed for the treatment of this condition, which causes pain, numbness and/or tingling in the hands and feet. The research was published March 28 in the Proceedings of the National Academy of Sciences. [More]
Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

Common antihistamine may partially reverse damage to visual system in multiple sclerosis patients

A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
Glial cells can modulate specific nerve endings in the brain, find Rockefeller scientists

Glial cells can modulate specific nerve endings in the brain, find Rockefeller scientists

More than half of our brains are made up of glial cells, which wrap around nerve fibers and insulate them--similarly to how the plastic casing of an electric cable insulates the copper wire within--allowing electrical and chemical impulses to travel faster. [More]
Research suggests new pathway for preventing optic nerve damage in KPro recipients

Research suggests new pathway for preventing optic nerve damage in KPro recipients

Researchers from Massachusetts Eye and Ear/Harvard Medical School have identified inflammatory factors that cause optic neuropathy in the back of the eye following implantation of a keratoprosthesis (KPro) — similar to what glaucoma patients experience, without the rise of pressure in the eye — and have shown that blocking one of those factors, tumor necrosis factor alpha (TNFa), successfully halts the development of optic nerve damage in a mouse model. [More]
Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment. [More]
Common genetic defect in beta cells may underlie both known forms of diabetes

Common genetic defect in beta cells may underlie both known forms of diabetes

New research by Dr. Sylvie Lesage, scientist at Maisonneuve-Rosemont Hospital and associate research Professor at University of Montreal, just published in the prestigious international scientific journal Nature Genetics, has discovered that a common genetic defect in beta cells may underlie both known forms of diabetes. [More]
Penn neurologists uncover new genetic cause of Charcot-Marie-Tooth Disease

Penn neurologists uncover new genetic cause of Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth Disease (CMT) is a family of inherited disorders of the peripheral nervous system, affecting approximately one in 2,500 Americans. Its most common iteration, CMT1, comes in many forms, most of which have to date been linked to a small set of causative genes. [More]
Neurofeedback decreases pain, increases quality of life in patients with neuropathic pain

Neurofeedback decreases pain, increases quality of life in patients with neuropathic pain

A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and increase quality of life in patients with neuropathic pain. [More]
FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

FDA approves Xalkori (crizotinib) to treat patients with ROS-1 positive NSCLC

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. [More]
Study provides first evidence that Zika virus may cause Guillain-Barré syndrome

Study provides first evidence that Zika virus may cause Guillain-Barré syndrome

Analysis of blood samples from 42 patients diagnosed with Guillain-Barré syndrome (GBS) during the Zika virus outbreak in French Polynesia provides the first evidence that Zika virus might cause GBS, a severe neurological disorder, according to new research published in The Lancet today. [More]
Promising therapeutic strategy for relieving neuropathic pain

Promising therapeutic strategy for relieving neuropathic pain

A specific molecule involved in maintaining pain after a nerve injury has been identified and blocked in mice by Hiroshima University researchers. These results reveal a promising therapeutic strategy for treating neuropathic pain. [More]
Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

A patient with recurrent metastatic colorectal cancer has been successfully treated with the angiotensin receptor blocker irbesartan, researchers report. [More]
MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

MDI Biological Laboratory scientist identifies potential drug therapy to reverse peripheral nerve damage

The Mount Desert Island Biological Laboratory has announced that assistant professor Sandra Rieger, Ph.D., has identified two drugs that could potentially be used to reverse peripheral nerve damage, or peripheral neuropathy, resulting from chemotherapy treatment for ovarian, breast, lung, pancreas and other cancers. The drugs also have potential applications for the treatment of peripheral nerve damage caused by diabetes, traumatic injuries and other conditions. [More]
Study reveals association between DNA methylation and type 2 diabetes

Study reveals association between DNA methylation and type 2 diabetes

Researchers from the Hospital del Mar Medical Research Institute have found an epigenetic mechanism implicated in the regulation of blood sugar. The study, published in the journal Molecular Human Genetics, reveals that the methylation of the TXNIP gene is associated with diabetes mellitus type 2 and, in particular, average blood glucose levels. [More]
RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S. [More]
Advertisement
Advertisement